Walgreens, LabCorp to open 600 patient service centers
Oct. 12, 2018—Walgreens and LabCorp will open at least 600 LabCorp patient service centers at Walgreens stores across the United States over the next four years.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Qiagen launches QIAamp PowerFecal Pro DNA Kit
Oct. 8, 2018—Qiagen announced the worldwide launch of the QIAamp PowerFecal Pro DNA Kit, for the extraction of high-quality DNA from fecal and gut samples.
Hemlibra for hemophilia A without FVIII inhibitors approved
Oct. 5, 2018—Roche announced the FDA’s approval of Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.
Therascreen EGFR RGQ PCR kit approved as CDx
Oct. 1, 2018—Qiagen announced that the FDA has approved a PMA supplement expanding the labeling claim of the Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or an exon 21 L858R mutation.
Roche announces availability of FoundationOne Liquid
Sept. 27, 2018—Roche announced that its FoundationOne Liquid, a blood-based genomic profiling test, is available worldwide. FoundationOne Liquid can identify circulating tumor DNA in the blood of people with cancer and can identify 70 of the most commonly mutated genes in solid tumors, including microsatellite instability.
Beckman releases new version of middleware
Sept. 12, 2018–Beckman Coulter launched version 1.10 of its Remisol Advance middleware system for mid- to high-volume laboratories. Enhancements include a centralized dashboard that combines sample status information (pending, stat, validated, and processed), turnaround time data, and quality control alerts in an intuitive format. “By providing a snapshot display of important analytics in a single location, we are enabling technologists to identify and prioritize critical activities moment by moment,” Erik Johnson, vice president and general manager of workflow and informatics
Fingerstick Sofia 2 Lyme FIA gets FDA clearance, CLIA waiver
Sept. 6, 2018—Quidel has received 510(k) clearance and Clinical Laboratory Improvement Amendments waiver from the FDA to market its Sofia 2 Lyme FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from fingerstick whole blood specimens from patients suspected of B. burgdorferi infection. The test is intended for use with the Sofia 2 analyzer to aid in the diagnosis of Lyme disease. The Sofia 2 Lyme
Study: SelectMDx cost-effective in four European countries
Aug. 30, 2018—MDxHealth announced that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases (Govers TM, et al. Epub ahead of print Aug. 20, 2018. doi:10.1038/s41391-018-0076-3). The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen. The model used in the study
Agena, PerkinElmer team up
Aug. 24, 2018—Agena Bioscience announced it has entered into a collaboration with PerkinElmer, incorporating the LabChip GX Touch nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassArray system. The companies have focused on targeting ctDNA in oncology liquid biopsy, where the combined systems aim to support a low cost, highly robust, single-day sample-to-results workflow for laboratories. PerkinElmer’s LabChip GX Touch nucleic acid analyzer provides electrophoretic visual quality assessment and quantitation down to
Sysmex enhances customer training with new learning center
Aug. 23, 2018—Sysmex has opened a state-of-the-art 98,000-square-foot Center for Learning in Vernon Hills, Ill. The multimillion-dollar facility provides a training environment for 3,000 customers—who will be taught virtually and on site—and 1,400 Sysmex employees annually. It has more than triple the training capacity of the previous Center for Learning, with two conventional classrooms for laboratory professionals and six classrooms for Sysmex technical engineers, the company reports. The facility also houses seven broadcast studios for virtual instructor-led training. The studios